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Purpose: We investigated the potential short and long-term effects in cultured human trabecular meshwork (TM) cells
of various topical glaucoma formulations containing different preservatives.
Methods: We tested the fixed combination medications 0.004% travoprost plus 0.5% timolol preserved with either 0.015%
benzalkonium chloride (BAK; DuoTrav®), or with 0.001% polyquad (PQ; DuoTrav® BAK-free); and 0.005% latanoprost
plus 0.5% timolol preserved with 0.020% BAK (Xalacom®). Also tested was a range of BAK concentrations (0.001%–
0.020%) in balanced salt solution (BSS). Cells were treated for 25 min at 37 °C with solutions diluted 1:10 and 1:100 to
mimic the reduced penetration of topical preparations to the anterior chamber. The percentage of live cells was determined
immediately after treatment through the uptake of the fluorescent vital dye calcein-AM. To determine any long-term
effects, we assayed release of matrix metalloproteinase 9 (MMP-9) and apoptosis 24 h after treatments.
Results: BAK demonstrated a dose-dependent reduction in TM cell viability, ranging from 71±5% live cells at 0.001%
BAK (diluted 1:10) to 33±3% live cells at 0.020% BAK (diluted 1:10). Travoprost (0.004%) plus 0.5% timolol preserved
with 0.015% BAK had statistically fewer live TM cells (79±7%) than the same preparation preserved with 0.001%
polyquad® (PQ; 93±1%; p<0.001). Latanoprost plus timolol preserved with 0.020% BAK (29±9% live cells) was similar
to the 0.020% BAK (33±3%) treatment. However, travoprost plus timolol preserved in 0.015% BAK had significantly
more live cells (83±12%) than the 1:10 dilution of 0.015% BAK (49±10%). We also found 0.020% BAK (diluted 1:100)
resulted in elevated levels of extracellular MMP-9 at 24 h.
Conclusions: These results demonstrate that the substitution of the preservative BAK from topical ophthalmic drugs
results in greater in vitro viability of TM cells. Travoprost with timolol, but not latanoprost with timolol, countered some
of the toxic BAK effects. BAK treatment appeared to cause elevated levels of MMP-9, a matrix metalloproteinase
implicated in the pathogenesis of glaucoma.
One of the commonly prescribed classes of intraocular
pressure (IOP) lowering agents are the prostaglandin analogs
(PGAs).  PGAs  act  primarily  by  enhancing  uveoscleral
outflow of aqueous humor, however PGAs also appear to act
on the trabecular meshwork (TM) to facilitate aqueous humor
(AH)  outflow  through  the  conventional  outflow  pathway
[1-3]. The beta adrenergic receptor antagonist (β-blocker; BB)
timolol, which reduces IOP by reducing AH production, is
often combined with PGAs as a second-line treatment after
initial  PGA  monotherapy  has  failed  (PGA+BB).  Use  of
topical ophthalmic formulations with two hypotensive agents
in a single bottle (fixed combination drug therapy) is a cost
effective  way  to  treat  glaucoma,  simplifies  the  treatment
regimen, and has the added benefit of decreasing the number
of  daily  exposures  to  the  medications  and  preservatives
contained in most topical ophthalmic preparations.
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Human  and  animal  studies  have  shown  that  chronic
topical glaucoma therapy associated with daily use can lead
to alterations in tear film, damage and remodeling of the
corneal surface, an increase in inflammatory cytokines, as
well as other deleterious effects [4-9]. Acute exposure models
using animals or cell culture systems demonstrate significant
damage/death  to  cornea  and  conjunctival  cells  either
immediately after exposure or within 24 h [10-14]. Some
toxicity can be attributed to either of the active ingredients of
the PGA+BB fixed combination therapy [14,15]. However,
much of the ocular surface changes seen with chronic daily
topical glaucoma therapy are associated with the commonly
used preservative, benzalkonium chloride (BAK) [7,8,16].
It  has  long  been  known  that  BAK  at  antiseptic
concentrations increases corneal permeability to hydrophilic
agents [17]. While this can potentially increase delivery of
topically  applied  drugs  to  the  aqueous  humor  (AH)  and
ultimately the sites of AH production and AH outflow, it
would also increase delivery of BAK itself. Little is known
about the long-term effects of BAK on the TM endothelial
cells that populate this conventional outflow pathway. The
aim  of  this  study  was  to  compare  the  in  vitro  effects  on
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1806cultured TM cells of three formulations of PGA+BB fixed
combination therapies preserved with either BAK (varying
concentrations) or the related cationic polymer polyquad (PQ:
0.001%). We assayed the effects of these agents diluted 1:10
and 1:100 to mimic the concentrations that reach the anterior
chamber.
METHODS
Test  and  control  solutions  for  cell  treatment:  Topical
ophthalmic  preparations  included  0.004%  travoprost  plus
0.5%  timolol  with  0.015%  BAK  (DuoTrav®;  Alcon
Laboratories, Inc., Fort Worth, TX), 0.004% travoprost plus
0.5% timolol with 0.001% PQ (DuoTrav® BAK-free; Alcon),
and 0.005% latanoprost plus 0.5% timolol with 0.020% BAK
(Xalacom®; Pfizer Inc., New York, NY). Not all of these
therapies are commercially available in the United States.
Also tested were a range of BAK solutions (0.001%, 0.005%,
0.010%, 0.015%, and 0.020%) in balanced salt solution (BSS;
Alcon). For viability assays, the live control solution was BSS
and  the  dead  control  solution  was  a  fixative  solution
containing 70% methanol and 0.2% saponin in BSS.
Cell  culture  and  treatment  conditions:  TM42,  a  primary
human  trabecular  meshwork  cell  line,  was  grown  in
Dulbecco's  Modified  Eagle  Medium  (DMEM;  Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(FBS;  Invitrogen)  and  50  U/ml  penicillin  and  50/ml
streptomycin  (Invitrogen)  on  flasks  and  plates  previously
coated with 0.1% gelatin (Sigma-Aldrich, St. Louis, MO) for
2 h at 37 °C. For 96-well assays, approximately 5×104 TM
cells were plated into each well of a coated 96-well tray.
Fluorescent  assays  were  plated  in  black  opaque  plates
(Cellstar; Greiner Bio-One North America Inc., Monroe, NC),
while absorbance-based assays were plated in clear plates
(Cellstar).  Cells  were  assayed  upon  reaching  confluence,
usually between 2 and 3 days post-plating. For assays, culture
media from TM cells was removed by aspiration and exposed
to 100 μl of test or control solutions (diluted 1:10 or 1:100 in
serum-free DMEM) for 25 min at 37 °C and 5% CO2.
Cell  viability  assays:  The  LIVE/DEAD®  Viability/
Cytotoxicity Kit for mammalian cells (Invitrogen) was used
to  assay  cell  death  immediately  after  treatment  with  test
solutions. In this vital stain system, the Calcein-AM ‘LIVE’
stain accumulates in healthy cells due to non-specific cellular
esterase activity that cleaves the cell-permeable ‘AM’ moiety
from the dye. After 25 min of exposure, test and control
dilutions were aspirated and replaced with a 100 μl solution
of  2  μM  Calcein-AM  in  Dulbecco's  Phosphate-Buffered
Saline without Calcium or Magnesium (D-PBS; Invitrogen).
Uptake of fluorescent dye was quantified after 20 min in a
Synergy™  4  Multi-Mode  Microplate  Reader  using  the
Gen5™ Reader Control and Data Analysis Software using the
band-pass filter setting (BioTek, Winooski, VT). Live cells
were  quantified  by  determining  the  Calcein  fluorescence
(F528) collected at 528±20 nm from an excitation of 485±20
nm.  Fluorescent  data  were  analyzed  as  outlined  in  the
manufacturer’s instructions. F528 fluorescence was normalized
to the F528 fluorescence of the BSS-treated live controls (100%
live).
The Vybrant Cytotoxicity Assay Kit (Invitrogen) was
used to determine the death of TM cells cultured for 24 h after
exposure to test and control solutions (diluted 1:100). This kit
assays the release into the cell culture media of the exclusively
cytosolic  enzyme  glucose  6-phosphate  dehydrogenase
(G6PD) using a fluorescent substrate. G6PD is an essential
enzyme present in all cells and since it remains active for at
least  24  h  after  cell  death,  extracellular  G6PD  activity
correlates to the number of cell that have died. After 25 min
of exposure, test and control solutions were aspirated and
replaced with 100 µl of culture media. At 24 h, media was
removed from the TM cells and saved for G6PD and matrix
metalloproteinase  assays  (below).  G6PD  levels  were
quantified as outlined in the manufacturer’s instructions using
50  µl  of  TM  cell  culture  supernatant.  Briefly,  G6PD-
dependent  production  of  resorufin  was  determined
fluorescently  in  a  Synergy™  4  Multi-Mode  Microplate
Reader with excitation at 563 nm and emission collected at
587 nm. Fluorescent data were corrected by subtraction of
fluorescence  from  no  protein  blanks,  and  normalized  to
fluorescence from lysed TM cells (% total G6DP).
Matrix metalloproteinase assays: The colorimetric MMP-9
Human ELISA Kit (Invitrogen) was used to determine amount
of  matrix  metalloproteinase  9  (MMP9)  released  into  the
extracellular media in TM cells cultured for 24 h after a 25
min exposure to test and control solutions (diluted 1:100).
MMP-9  levels  were  quantified  as  outlined  in  the
manufacturer’s instructions using 40 µl of TM cell culture
supernatant  (isolated  as  described  above),  with  ELISA
absorbance  measurements  performed  at  450  nm  using  a
Synergy™ 4 Multi-Mode Microplate Reader and compared
to a MMP-9 standard curve.
Apoptosis measurements: The appearance of the apoptosis
marker  (activated  caspase-3)  was  determined  24  h  after
exposure to test solutions, cells undergoing apoptosis were
detected  by  immunofluorescence  using  an  antibody  for
cleaved  caspase-3.  Activation  of  caspase-3  requires  a
proteolytic  processing  of  the  inactive  pro-enzyme;  the
antibody used only recognizes this cleaved (active) form and
not the full-length form. TM cells were plated onto gelatin
coated glass coverslips and treated as described above. After
25 min exposure, test and control solutions (diluted 1:100)
were aspirated and replaced with culture media. At 24 h, cells
were fixed, permeabilized and stained using an Alexa Fluor
488-conjugated  antibody  specific  for  cleaved  Caspase-3
(Asp175; Cell Signaling, Beverly MA). Fluorescence imaging
was performed using a Nikon Eclipse 80i microscope (Nikon,
Melville, NY) equipped with a Nikon DS-Qi1 monochrome
1.5 megapixel CCD camera and a Nikon 10×/0.30 Plan Fluor
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photographed  for  counting  of  caspase-3  staining  (ranging
from 20 to 50 cells/field).
Data and statistical analysis: The two cell viability assays
were performed in two independent experiments in triplicate
(n=6).  MMP-9  assays  were  performed  in  duplicate.  Five
different field of views were counted for each exposure in the
apoptosis  assays  (n=5).  Data  were  reported  as  the  mean
±standard deviation. Statistical analysis was performed using
the  t-test  (Excel,  Microsoft;  Redmond  WA);  the  level  of
significance was set at p<0.05.
RESULTS
Toxicity of BAK alone: TM cells showed a dose-dependent
decrease in cell viability after exposure to BAK for 25 min
when  assayed  immediately  after  exposure  (Figure  1).  All
concentrations of diluted BAK were significantly different
(p<0.05) from BSS-treated controls. There was no significant
difference in cell viability between 1:10 dilutions of 0.001%
and  0.005%  BAK.  We  observed  statistically  significant
differences  in  TM  cell  viability  (*,  p<0.05)  among  1:10
dilutions  of  0.005%  BAK  (72±3%  live),  0.010%  BAK
(62±5% live), 0.015% BAK (49±10% live), and 0.020% BAK
(33±3% live).
TM cell survival with PGAs+BB preserved with BAK: TM
cells  exposed  to  1:10  dilutions  of  both  PGAs+BB
formulations  containing  BAK  had  statistically  significant
fewer  live  cells  compared  to  BSS  controls  (Figure  2,  *).
Comparing  the  two  BAK-preserved  formulations  of  PGA
+BB, exposure to diluted travoprost+timolol with 0.015%
BAK resulted in significantly more live TM cells (79±7%)
than  diluted  latanoprost+timolol  with  0.020%  BAK  (29%
±9%, p<0.05). As shown in Figure 2 (‡), TM cells exposed to
diluted travoprost+timolol with 0.015% BAK (79±7%) also
had significantly more live cells compared to diluted 0.015%
BAK (49±10% live cells). Cultures exposed to either diluted
latanoprost+timolol  with  0.020%  BAK  or  diluted  0.020%
BAK  had  similar  survival  rates  (29±9%  live  cells  versus
33±3%, p=0.29).
TM  cell  survival  with  PGA+BB  preserved  with  PQ:
Travoprost+timolol with PQ diluted 1:10 caused a slight but
significant reduction in the number of live TM cells (93%
±1%)  compared  to  BSS  exposure  (Figure  2,  *),  but  had
significantly more live cells compared to the same PGA+BB
formulation containing 0.015% BAK (79±7%, Figure 2, †).
TM cell survival with PGA+BB at 24 h: To determine the
long-term cytotoxic effects in TM cells, cultures were exposed
to a lower amount of test and control solutions (diluted 1:100)
in serum-free media. TM cells were then returned to culture
media and assayed after 24 h. Any TM cells which die over
this period would release into the extracellular media the
exclusively  cytosolic  enzyme  glucose  6-phosphate
dehydrogenase (G6PD). We found no significant differences
between cultures exposed of test and control solutions when
compared to BSS controls (Table 1).
TM cell survival with PGA+BB at 24 h: The release of matrix-
metalloproteinase 9 (MMP-9) into the extracellular media was
assayed  alongside  G6PD  release.  Using  an  assay  with  a
minimum sensitivity of 10 pg/mL, we could not reproducibly
detect MMP-9 in TM cells exposed to any of the PGAs+BB
formulations (diluted 1:100). Among the BAK solutions, we
could only reproducibly detect MMP-9 in cells treated with
1:100 dilution of 0.020% (33.4±8.8 pg/ml, n=2).
TM cell apoptosis with PGA+BB at 24 h: Apoptosis was
determined in TM cells 24 h after exposure to test and control
solutions (diluted 1:100). We found an inverse relationship
Figure  1.  Percent  of  live  trabecular
meshwork  (TM)  cells  after  a  25  min
exposure  to  various  concentrations  of
benzalkonium  chloride  (BAK  diluted
1:10 in serum-free media). The number
of  live  cells  was  normalized  to  the
number  of  live  cells  in  BSS-treated
controls. Data are reported as the mean
±standard deviation of n=6 replicates.
All  concentrations  of  BAK  were
significantly  different  (p<0.05)  from
BSS-treated controls. There is a dose-
dependent  decrease  in  cell  viability
above  0.005%  BAK  (diluted  1:10).
*=p<0.05.
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cells  (Table  2).  When  exposed  to  0.001%  BAK  (diluted
1:100),  we  counted  44.5%±8.1%  apoptotic  TM  cells
compared to 15.9%±6.5% after exposure to 0.005% BAK
(diluted 1:100), 12.8%±6.8% after exposure to 0.010% BAK
(diluted 1:100), and 13.2%±6.0% after exposure to 0.015%
BAK  (diluted  1:100).  TM  cells  exposed  to  0.020%  BAK
(diluted 1:100) showed no statistical increase in apoptosis
compared to BSS controls (5.8%±3.5% versus 4.4%±2.5%,
respectively).  This  effect  of  increasing  apoptosis  with
exposure to reducing concentrations of BAK is similar to that
reported in conjunctival cells [18].
TM cells exposed to any of the PGAs+BB formulations
(diluted  1:100)  had  statistically  more  apoptotic  TM  cells
compared to BSS controls (Table 2, *). Replacement of PQ
with  BAK  in  the  travoprost+timolol  fixed  combination
therapy has a small but not significant effect on apoptosis.
Exposure of TM cells to diluted latanoprost+timolol with
BAK resulted in significantly fewer apoptotic cells (11.9%
±4.6%) than exposure to either diluted travoprost+timolol
with BAK (18.7%±4.5%, Table 2, †) or diluted travoprost
+timolol  with  PQ  (15.3%±6.3%,  Table  2).  Since  lower
concentrations of BAK result in greater apoptosis of TM cells
by some unknown mechanism, the difference seen here may
Figure  2.  Percent  of  live  trabecular
meshwork  (TM)  cells  after  a  25  min
exposure  to  various  commercially
available prostaglandin analogs (diluted
1:10 in serum-free media). The number
of  live  cells  was  normalized  to  the
number  of  live  cells  in  BSS-treated
controls. Data are reported as the mean
±standard deviation of n=6 replicates.
*=p<0.05  versus  BSS  control;
†=p<0.05  versus  travoprost/timolol  +
PQ; ‡=p<0.05 versus BAK alone.
TABLE 1. RELEASE OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE (G6PD) BY TRABECULAR MESHWORK AT 24 H.
PGA+BB formulations (dil. 1:100) % Total G6PD
Travoprost+timolol with PQ 3.0%±1.5%
Travoprost+timolol with BAK 2.1%±0.1%







        TM cells were treated with test and control solutions (diluted 1:100) for 25 min, and then returned to fresh culture media. Media
        was assayed at 24 h (n=6), data were normalized to the amount of G6PD in lysed trabecular meshwork cells (100% G6PD, and
        expressed as mean±SD. No significant changes were noted from BSS control.
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latanoprost+timolol  formulation.  However,  since  diluted
latanoprost+timolol  with  BAK  caused  significantly  more
apoptosis than the corresponding amount of BAK (diluted
0.020%,  Table  2,  ‡),  this  suggests  that  the  increase  in
apoptosis is due to one of the active ingredients and not the
preservative.
DISCUSSION
The current study examined the effects of different dilutions
of  commonly  used  topical  ophthalmic  medications  either
immediately  after  exposure  or  after  24  h.  For  short-term
viability, we used vital dyes to distinguish live cells from dead
which  has  proven  to  be  a  useful  assay  to  determine  the
cytotoxicity of topical ophthalmic medications in cell culture
systems  that  model  acute  exposure  [10,13,14,19].  At  a
dilution  of  1:10,  we  determined  that  replacement  of
preservative  BAK  with  PQ  in  topical  fixed  combination
therapies (PGA+BB) significantly increased the number of
live  TM  cells  when  assayed  immediately  after  exposure.
When diluted to 1:100, we found no difference in the number
of dead cells among any of the PGA+BB and BAK solutions.
Exposure  to  concentrations  of  BAK  commonly  used  as
preservatives  in  topical  ophthalmic  preparations  (diluted
1:10)  are  toxic  to  TM  cells  in  a  direct  dose–response
relationship  when  assayed  immediately  after  exposure.  In
fixed combination therapies preserved with BAK, we found
that  exposure  to  travoprost+timolol  resulted  in  greater
percentage of live cells than latanoprost+timolol. We believe
that some of this greater survival can be attributed to the lower
concentration of BAK. However, we found that an inverse
relationship between exposure to BAK diluted 1:100 and TM
cell apoptosis at 24 h. The latanoprost+timolol exposure had
fewer apoptotic cells than the travoprost+timolol exposure.
This is likely due to the higher concentration of BAK in the
latanoprost+timolol  formulation.  Our  results  mirror  the
apoptotic effect of BAK seen by others in conjunctival cells,
in  which  BAK  caused  immediate  necrosis  at  high
concentrations,  but  apoptosis  after  treatment  with  low
concentrations [18]. These researchers concluded that BAK
caused  immediate  necrosis  at  high  concentrations,  but
apoptosis after treatment with low concentrations. Currently,
we have no explanation for why apoptosis is seen only at the
lowest concentrations of BAK.
We  also  determined  that  exposure  to  0.020%  BAK
(diluted 1:100) increased MMP-9 release by TM cells over 24
h, but not with exposure to diluted PGA+BB formulations
preserved with BAK. The detection of MMP-9 in the TM can
be  problematic,  and  may  depend  on  the  method  used  for
detection. One group reported near zero levels of MMP-9
mRNA in cultured TM cells [20] while other groups have
detected  MMP-9  enzymatic  activity  in  cultured  TM  cells
cultures [21]. Increased MMP-9 activity was reported in TM
organ cultures exposed to latanoprost at concentrations 20-
fold higher than that used here [22]. In contrast, Oh et al.
[20]  found  no  increase  in  expression  MMP-9  in  TM  cell
cultures exposed to concentrations latanoprost similar to that
used  here.  However,  to  our  knowledge,  no  group  has
examined MMP-9 in TM cells exposure to diluted BAK alone.
In this light, the effect of MMP-9 on the collagen matrix of
the TM region is a question for future studies.
In our short-term viability assays, it is notable that diluted
travoprost+timolol with 0.015% BAK performed better than
0.015% BAK alone, reflecting the protective effect that some
prostaglandins demonstrate against the toxic effect of BAK in
ocular surface epithelia [23]. A protective effect was not seen
with  latanoprost+timolol  with  0.020%  BAK  in  short-term
viability assays; this result is in agreement with our previous
cytotoxic assays in corneal and conjunctival using this vital
dye system [24], but these results are in contrast to Guenoun
et  al.  [23]  who  found  a  protective  effect  with  both
TABLE 2. CLEAVED CASPASE-3 POSITIVE TRABECULAR MESHWORK CELLS AT 24 H.
PGA+BB formulations (dil. 1:100) % Apoptotic cells
Travoprost+timolol with PQ 15.3%±6.3%*
Travoprost+timolol with BAK 18.7%±4.5%*
Latanoprost+timolol with BAK 11.9%±4.6%*†‡







        TM cells were treated with test and control solutions (diluted 1:100) for 25 min, and then returned to fresh culture media. Cells
        were fixed and immunostained for cleaved caspase-3 at 24 h. Data are reported as the percent of cleaved caspase-3 positive cells
        ±SD (n=5). *p<0.05 versus BSS; †=p<0.05 versus travoprost+timolol with BAK; ‡=p<0.05 versus BAK alone.
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conjunctival cells.
Benzalkonium chloride (BAK) is the most commonly
used preservative in topical glaucoma medications [25]. BAK
is a quaternary ammonium compound that acts as a detergent,
disrupting bacterial cell membranes and ultimately killing
them. There is a broad consensus that chronic use of topical
glaucoma  medications  is  associated  with  ocular  surface
changes  in  both  the  cornea  and  conjunctiva,  and  several
studies have linked these effects to the BAK content, both in
vitro and in vivo, on the corneal and conjunctival epithelium
and  stroma  [6,10,15,23,26-28].  While  the  antiseptic
concentrations of BAK are cytotoxic, it is important to also
consider  the  toxicity  of  the  active  ingredients.  A100-fold
dilution of a therapeutic dose of PGAs can increase the release
of cytosolic proteins from corneal endothelial cells, while a
1:100  dilution  of  0.01%  BAK  does  not  [14].  Similarly,
undiluted  BB  in  a  preservative-free  formulation  causes  a
40%–60% reduction in viability of human conjunctival cells
[15].
The choice of BAK concentration and dosing regimen for
an experimental animal model can greatly affect the outcome
of BAK. For example, single daily dosing in rabbits for 30
days with 0.010% BAK showed minimal damage to corneal
endothelial cells [29], but single daily dosing of PGA plus
0.020% BAK did show a reduction in goblet cell density and
increase in inflammatory cells [7,30]. In contrast, instilling
multiple doses over a short period of time (the Draize model),
has  shown  changes  to  the  ocular  surface  within  one  day,
causing corneal/conjunctival cellular damage and an increase
in inflammatory markers [11]. Therefore it is important to
balance exposure time and concentration when evaluating the
biologic effect of topical ophthalmic medications. While our
exposure model does not model the repetitive exposure to
topical  ocular  drugs  experienced  in  vivo,  the  lower
concentration  of  exposure  is  a  good  model  for  the
accumulation of drug and preservative in the AH, and is a first
a step in understanding the role of glaucoma therapy in ocular
surface disease.
In conclusion, our findings argue that replacement of
BAK  with  an  alternate  preservative  (PQ)  is  potentially
beneficial for TM cell viability. Since glaucoma is a chronic
disease, it is important to consider the consequences of long-
term exposure to both the anti-hypotensive agent as well as
the  included  preservative.  Studies  in  rabbits  and  humans
demonstrate penetration of PGAs to the AH to be less than
1/1000th of the concentration applied [31,32]. Topical BAK
has been shown to increased fluorescein permeability in rabbit
cornea [17], and reduces the expression of the tight-junction
protein occludin in a corneal cell culture system [33]. These
findings, combined with the fact that BAK is itself absorbed
and  accumulates  into  ocular  tissues  [34],  imply  that  the
concentration of BAK in the AH may be much higher than the
PGA  levels.  Since  prior  studies  have  shown  that  brief
treatment  of  cultured  TM  cells  with  BAK  can  increase
apoptotic cell markers and significantly decrease cell growth
at levels 1/100th of that used as a preservative [35,36], the
deleterious  effect  of  BAK  on  TM  cells  may  be  an
underappreciated concern. Furthermore, since the number of
live  TM  cells  within  the  meshwork  was  found  to  be
statistically  lower  in  patients  with  primary  open-angle
glaucoma [37], maintaining TM cell number should be as
important  a  metric  of  disease  treatment  as  intraocular
pressure. The clinical implications of our findings suggest that
long-term use of fixed combination therapies containing BAK
could damage the structures within the TM by reducing the
number of healthy TM cells. Therefore, replacement of BAK
with  PQ  within  topical  glaucoma  therapies  may  slow  or
prevent further damage to the TM region of the eye. This study
also raises the question of whether activation of MMP-9 by
BAK plays a positive or negative role in fluid flow through
the TM. Additional in vitro studies are needed, and in vivo
animal assays will need to be performed to ascertain the true
clinical  implications  of  our  findings  for  patients  treated
chronically  with  fixed  combination  topical  ophthalmic
preparations.
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